361 Shares in Eli Lilly and Company (NYSE:LLY) Purchased by Resolute Advisors LLC

Resolute Advisors LLC purchased a new position in shares of Eli Lilly and Company (NYSE:LLY - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 361 shares of the company's stock, valued at approximately $279,000.

Other hedge funds have also recently modified their holdings of the company. Annis Gardner Whiting Capital Advisors LLC increased its holdings in Eli Lilly and Company by 9.2% in the 4th quarter. Annis Gardner Whiting Capital Advisors LLC now owns 986 shares of the company's stock worth $761,000 after acquiring an additional 83 shares in the last quarter. Grant Private Wealth Management Inc bought a new position in shares of Eli Lilly and Company in the fourth quarter worth approximately $301,000. Arete Wealth Advisors LLC increased its stake in shares of Eli Lilly and Company by 37.1% in the fourth quarter. Arete Wealth Advisors LLC now owns 7,454 shares of the company's stock worth $5,750,000 after purchasing an additional 2,016 shares in the last quarter. Motley Fool Asset Management LLC raised its position in shares of Eli Lilly and Company by 0.9% during the 4th quarter. Motley Fool Asset Management LLC now owns 39,375 shares of the company's stock valued at $30,398,000 after purchasing an additional 370 shares during the period. Finally, World Investment Advisors lifted its stake in shares of Eli Lilly and Company by 14.9% during the 4th quarter. World Investment Advisors now owns 16,574 shares of the company's stock valued at $12,795,000 after buying an additional 2,145 shares in the last quarter. Institutional investors own 82.53% of the company's stock.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on LLY shares. Wells Fargo & Company increased their price target on Eli Lilly and Company from $970.00 to $1,100.00 and gave the stock an "overweight" rating in a research note on Wednesday, March 5th. Leerink Partners set a $950.00 target price on Eli Lilly and Company in a research report on Friday, January 17th. Berenberg Bank set a $970.00 price target on Eli Lilly and Company in a report on Thursday, January 16th. StockNews.com upgraded Eli Lilly and Company from a "hold" rating to a "buy" rating in a research note on Friday, February 7th. Finally, Truist Financial lifted their price objective on shares of Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the company a "buy" rating in a research report on Monday, February 3rd. Three equities research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $1,009.72.

Remove Ads

Eli Lilly and Company Trading Down 6.5 %

LLY traded down $51.53 on Friday, hitting $737.56. The company had a trading volume of 5,289,016 shares, compared to its average volume of 3,322,098. The business's fifty day simple moving average is $848.36 and its 200 day simple moving average is $832.44. The company has a quick ratio of 0.97, a current ratio of 1.15 and a debt-to-equity ratio of 2.00. Eli Lilly and Company has a 12-month low of $706.96 and a 12-month high of $972.53. The company has a market cap of $699.33 billion, a PE ratio of 62.99, a PEG ratio of 1.40 and a beta of 0.34.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its earnings results on Thursday, February 6th. The company reported $5.32 earnings per share for the quarter, missing the consensus estimate of $5.45 by ($0.13). Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. Equities research analysts expect that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company declared that its board has initiated a share buyback plan on Monday, December 9th that allows the company to buyback $15.00 billion in shares. This buyback authorization allows the company to buy up to 2% of its stock through open market purchases. Stock buyback plans are generally an indication that the company's leadership believes its shares are undervalued.

Insider Activity

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 1,000 shares of the business's stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $818.24, for a total transaction of $818,240.00. Following the completion of the transaction, the chief accounting officer now owns 5,840 shares in the company, valued at $4,778,521.60. The trade was a 14.62 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders own 0.13% of the company's stock.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.